Name: UMIN ID:
Unique ID issued by UMIN | UMIN000007413 |
---|---|
Receipt number | R000008734 |
Scientific Title | Phase II Study of Safety and Efficacy. Dasatinib in Patients with Chronic Phase Chronic Myelogenous Leukemia achieving a Major Molecular Response on Imatinib. |
Date of disclosure of the study information | 2012/03/01 |
Last modified on | 2020/09/07 11:16:01 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2012/03/01 10:00:28 | ||
2 | Update | 2012/03/01 10:14:40 | Key exclusion criteria |
|
3 | Update | 2012/03/02 15:27:20 | Institutions |
|
4 | Update | 2012/05/29 11:44:02 | Recruitment status |
|
5 | Update | 2012/10/01 09:35:15 | Email Email1 Institutions |
|
6 | Update | 2012/10/17 14:14:10 | Email Email1 |
|
7 | Update | 2013/03/01 09:19:54 | Institutions |
|
8 | Update | 2013/09/01 09:08:25 | Email Institutions |
|
9 | Update | 2015/03/30 17:19:23 | Recruitment status |
|
10 | Update | 2016/12/14 16:06:44 | Key inclusion criteria |
|
11 | Update | 2016/12/14 16:07:32 | Name of primary person or sponsor Organization |
|
12 | Update | 2020/09/07 11:08:44 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Address Email1 Organization Organization Address Address Tel |
|
13 | Update | 2020/09/07 11:10:44 | Number of participants that the trial has enrolled |
|
14 | Update | 2020/09/07 11:13:31 | Recruitment status Date of IRB Last follow-up date |
|
15 | Update | 2020/09/07 11:15:34 | Recruitment status |
|
16 | Update | 2020/09/07 11:16:01 | Recruitment status |